Press Releases

Albumedix Announces Appointment of Gregor Kawaletz as Chief Commercial Officer

PRESS RELEASE: Nottingham, UK, June 1, 2020 – Albumedix Ltd. (‘Albumedix’), the world leader in recombinant human albumin (rAlb), announced today the strengthening of its Executive Leadership with the appointment of Gregor Kawaletz as Chief Commercial Officer, as of June 1st, 2020. This announcement follows the recent appointment of Jonas Skjødt Møller as Chief Executive Officer of Albumedix and is part of the company’s global growth strategy.

UCB and N-SIDE increase their strategic collaboration

N-SIDE announced that UCB has signed a 3-year agreement increasing their collaboration in clinical supply optimization. UCB will use the N-SIDE Suite for Clinical Trials solution and N-SIDE consulting services to optimize the supply management from protocol design to on-going clinical trials.

ERT Survey Indicates Swift Adoption of Virtual Clinical Trials Due to COVID-19

82% respond that they are implementing elements of virtual trials due to the pandemic

Clinical Ink Implements COVID-19 Therapy Trial in Three Weeks

Clinical Ink, a global clinical trial technology company, helped expedite the study of a treatment for cytokine storm, the immunological reaction associated with severe cases of COVID-19. Clinical Ink purpose-built and deployed the electronic study environment in just 15 business days.

Noxopharm Reports Veyonda’s Potential in Late-Stage Cancer at ASCO 2020

At the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting, Noxopharm, a clinical-stage Australian oncology drug development company, has reported two sets of clinical data relating to the development of NOX66 (Veyonda®) as a treatment for end-stage cancer.

The Future of Pharmacy: Celerion Expands Its Purpose-Built, USP-Compliant Pharmacy Capabilities Across Facilities

Celerion announced today the multimillion-dollar expansion of specialized pharmacies across their clinical research units in North America, demonstrating their commitment to further assisting sponsors in meeting the forthcoming USP requirements for compounding investigational drug product in support of early phase clinical trial research.

ERT Virtual Visit Capabilities Keep Clinical Trials on Track during COVID-19

Seamless, dynamic solution enables continued interactions between clinical trial patients and investigative sites

Ubiquitome’s Liberty16 attracts Swiss giant

Ubiquitome has signed an exclusive agreement for Swiss headquartered DKSH to market and sell its mobile, battery powered COVID-19 tester, Liberty16, in several Asia Pacific countries. The agreement comes on the back of Ubiquitome recently receiving just over half a million dollars in New Zealand Government funding to help with increasing the manufacturing capacity for the Liberty16.

Panasonic produces prototype breathing devices to assist COVID-19 patients

The team at Panasonic Manufacturing UK’s facility in Cardiff have produced 80 prototype breathing devices to assist hospital patients suffering from COVID-19.

ActiGraph Announces Acquisition by ArchiMed

ActiGraph, a leading provider of medical-grade wearable physical activity and sleep monitoring solutions for the global scientific community, announced today that it has been acquired by global private equity healthcare specialist ArchiMed.

Rho to Coordinate Study Sponsored by National Institute of Allergy and Infectious Diseases to Determine Rate of COVID-19 Infection in US Children

Rho to Coordinate Study Sponsored by National Institute of Allergy and Infectious Diseases to Determine Rate of COVID-19 Infection in US Children NIH-funded study also aims to identify percentage of children infected with the new coronavirus that develop symptoms of the disease Research Triangle Park, NC – May 21, 2020 – Rho, a full-service contract research organization (CRO) with a proven track record of drug development success, today announced it is coordinating a new study, called Human Epidemiology and Response to SARS-CoV-2 (HEROS), to help determine the rate of the new coronavirus infection in children and their family members in the U.S. The study also aims to determine what percentage of children infected with SARS-CoV-2, the virus that causes COVID-19, develop symptoms of the disease, as well as whether rates of SARS-CoV-2 infection differ between children who have asthma or other allergic conditions and children who do not. HEROS is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Creative BioMart Introduced Protein Network Construction and Topological Structure Analysis Service

Profacgen Released Lactic Acid Bacteria Fermentation Service

Negative-pressure Wound Therapy (NPWT) Devices Market Key Players, Industry Overview and Forecast Analysis

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

ALBUMEDIX ANNOUNCE JONAS SKJØDT MØLLER AS NEW CHIEF EXECUTIVE OFFICER

Crucial Data Solutions Forms Partnership with Durham Tech to Support Clinical Research Education

Durham Tech’s clinical trials program utilizes TrialKit, a data collection and study management platform from Crucial Data Solutions

Alfa Chemistry Offers PEG linkers for the Science Community in Bioconjugation and Pegylation

Alfa Chemistry announced that a total of close to 800 PEG linker products are now available for its customers worldwide.

AI & Medicine — An Expert in AI-aided Drug Discovery and Medical Applications

AI & Medicine successfully develops an AI-powered drug discovery platform for medical institutions and pharmaceutical enterprises across the globe.

eClinical Solutions Unveils Roadmap for Clinical Trials During COVID-19 Pandemic

With 60% of trials on hold, Boston pharma tech innovator offers a route for advancing drug development using AI and novel data strategies

Clinical Ink Study Assurance Program Waives Millions of Dollars in Change Order Fees for Ongoing Clinical Trials

Clinical Ink has announced a wide-ranging Study Assurance Program to minimize financial impact of the disruption from COVID-19 on new and existing clinical trials.